Clinical Trials Directory

Trials / Unknown

UnknownNCT02368613

A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Daewon Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of hypercholesterolemia patients by conducting phase 2a. 4 groups involving placebo group, each groups are composed by 16, will be participated in this trial.

Conditions

Interventions

TypeNameDescription
DRUGDW-3102

Timeline

Primary completion
2017-10-01
First posted
2015-02-23
Last updated
2016-10-10

Source: ClinicalTrials.gov record NCT02368613. Inclusion in this directory is not an endorsement.

A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients (NCT02368613) · Clinical Trials Directory